Immune Thrombocytopenia, Pregnancy
Conditions
Keywords
recombinant human thrombopoietin, immune thrombocytopenia, pregnancy
Brief summary
The project was undertaking by Qilu Hospital of Shandong University and other well-known hospitals in China. Aims at evaluating efficacy and safety of rhTPO in management of ITP in pregnancy.
Detailed description
The investigators are undertaking a multicenter, open-labeled, pilot study of 30 ITP patients in pregnancy from Qilu Hospital of Shandong University and other well-known hospitals in China. ITP patients in pregnancy who failed to respond to prednisone, IVIG and developed refractoriness to platelet transfusion will be given rhTPO intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week. Platelet count, bleeding and other symptoms will be evaluated before and after treatment. Adverse events will be recorded throughout the study.
Interventions
DRUGrhTPO
Sponsors
The Affiliated Hospital of Qingdao University
The Second Hospital of Hebei Medical University
Institute of Hematology & Blood Diseases Hospital, China
Southern Medical University, China
Shandong University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1. Subject is between 18-50 years old. 2. After 12 weeks gestation. 3. Diagnosed with ITP meeting the diagnostic criteria for immune thrombocytopenia. 4. Patients who have no response or relapsed after Corticosteroid or IVIG. 5. Patients developed refractoriness to platelet transfusion. 6. To show a platelet count \< 30×10\^9/L, and with bleeding manifestations. 7. Willing and able to sign written informed consent.
Exclusion criteria
1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit. 2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit. 3. Current HIV infection or hepatitis B virus or hepatitis C virus infections. 4. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 5. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test. 6. Patients who are deemed unsuitable for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Early response 1- Response rate (CR+R) | 7th day | Response rate (CR+R) at the 7th day. CR is defined as platelet count ≥ 100×10\^9/L, and R is defined as platelet count of \>30×10\^9/L with at least a doubling of the baseline value. |
| Early response 2- Response rate (CR+R) | 14th day | Response rate (CR+R) at the 14th day. |
| Long-time response 1 (Platelet count) | 10th week | Platelet count at 10th week. |
| Long-time response 2 (Platelet count) | 40 weeks' gestation | Platelet count at 40 weeks' gestation. |
| Long-time response 3 (Platelet count) | one month after delivery | Platelet count one month after delivery. |
| Safety (Adverse events) | 6 months after delivery | Adverse events in patients and infants. |
Countries
China
Outcome results
None listed